Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2351045 | PMC |
http://dx.doi.org/10.1136/bmj.312.7041.1291 | DOI Listing |
Nat Commun
December 2024
Institute of Pathology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
Pathogenic activating mutations in the fibroblast growth factor receptor 3 (FGFR3) drive disease maintenance and progression in urothelial cancer. 10-15% of muscle-invasive and metastatic urothelial cancer (MIBC/mUC) are FGFR3-mutant. Selective targeting of FGFR3 hotspot mutations with tyrosine kinase inhibitors (e.
View Article and Find Full Text PDFPediatr Neurol
November 2024
Subdirection of Basic Research, Instituto Nacional de Cancerología, Mexico City, Mexico; ABC Medical Center, Mexico City, Mexico. Electronic address:
Aktuelle Urol
December 2024
Allgemeine und geriatrische Rehabilitation, Klinik Wartenberg, Wartenberg, Germany.
Clin Genitourin Cancer
February 2025
Urology department, Faculty of Medicine of ABC (FMABC), São Paulo, Brazil.
Urol Oncol
November 2024
Department of Urology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!